E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy
European Journal of Pain · 2025
DOI: 10.1002/ejp.4755 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Pain, 2025. Verfasst von Rafael Gálvez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pain Clinic, Virgen de Las Nieves University Hospital, Granada, Spain. Hauptthemen laut MEDLINE: Receptors, sigma, Diabetic Neuropathies, Sigma-1 Receptor, Postoperative Pain. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
We report the efficacy and safety of E‐52862—a selective, sigma‐1 receptor antagonist—from phase 2, randomized, proof‐of‐concept studies in patients with moderate‐to‐severe, neuropathic, chronic postsurgical pain (CPSP) and painful diabetic neuropathy (PDN).
Methods
Adult patients (CPSP [ N = 116]; PDN [ N = 163]) were randomized at a 1:1 ratio to 4 weeks of treatment with E‐52862 (CPSP [ n = 55]; PDN [ n = 85]) or placebo (CPSP [ n = 61]; PDN [ n = 78]) orally once daily. Pain intensity scores were measured using a numerical pain rating scale from 0 (no pain) to 10 (worst pain imaginable). The primary analysis population comprised patients who received study drug with ≥1 baseline and on‐treatment observation (full analysis set).
Results
In CPSP, mean baseline average pain was 6.2 for E‐52862 vs. 6.5 for placebo. Week 4 mean change from baseline (CFB) for average pain was −1.6 for E‐52862 vs. –0.9 for placebo (least squares mean difference [LSMD]: −0.9; p = 0.029). In PDN, mean baseline average pain was 5.3 for E‐52862 vs. 5.4 for placebo. Week 4 mean CFB for average pain was −2.2 for E‐52862 vs. –2.1 for placebo (LSMD: –0.1; p = 0.766). Treatment‐emergent adverse events (TEAEs) were reported in 90.9% of E‐52862‐treated patients vs. 76.7% of placebo‐treated patients in CPSP and 34.1% vs. 26.9% in PDN. Serious TEAEs occurred in CPSP only: E‐52862: 5.5%; placebo: 6.7%.
Conclusions
E‐52862 demonstrated superior relief of CPSP vs. placebo after 4 weeks. Reductions in pain intensity were seen in PDN with E‐52862; high placebo response rates may have prevented differentiation between treatments. E‐52862 had acceptable tolerability in both populations. Significance Statement These proof‐of‐concept studies validate the mode of action of E‐52862, a selective sigma‐1 receptor antagonist. In CPSP, E‐52862 resulted in clinically meaningful pain relief. In PDN, reductions in pain intensity were seen with E‐52862; high placebo response rates may have prevented differentiation between E‐52862 and placebo. These findings are clinically relevant given that neuropathic pain is highly incapacitating, lacking effective treatments and representing a significant unmet medical need, and support further development of sigma‐1 receptor antagonists for peripheral neuropathic pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pain Clinic, Virgen de Las Nieves University Hospital, Granada, Spain.
- Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
- ESTEVE Pharmaceuticals S.A., Barcelona, Spain.
- Pain Unit, Vall d'Hebron Research Institute, Barcelona, Spain.
- Pain Unit, Hospital del Mar Research Institute, Barcelona, Spain.
- Puerto Real University Hospital, Cádiz, Spain.
ORCID-Profile: Rafael Gálvez, Victor Mayoral, Jesús Cebrecos, Francisco J Medel, Adelaida Morte, Mariano Sust, Anna Vaqué, Antonio Montes-Pérez, Fernando Neira-Reina, Luz Cánovas, César Margarit, Didier Bouhassira
Zitieren
APA
Gálvez, R., Mayoral, V., Cebrecos, J., Medel, F. J., Morte, A., Sust, M., Vaqué, A., Montes-Pérez, A., Neira-Reina, F., Cánovas, L., Margarit, C., & Bouhassira, D. (2025). E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy. European Journal of Pain. https://doi.org/10.1002/ejp.4755
Vancouver
Gálvez R, Mayoral V, Cebrecos J, Medel FJ, Morte A, Sust M, et al. E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy. European Journal of Pain. 2025. doi:10.1002/ejp.4755
BibTeX
@article{Glvez2025,
author = {Gálvez, Rafael and Mayoral, Victor and Cebrecos, Jesús and Medel, Francisco J and Morte, Adelaida and Sust, Mariano and Vaqué, Anna and Montes-Pérez, Antonio and Neira-Reina, Fernando and Cánovas, Luz and Margarit, César and Bouhassira, Didier},
title = {E‐52862—A selective sigma‐1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double‐blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy},
journal = {European Journal of Pain},
year = {2025},
doi = {10.1002/ejp.4755}
}
EUVIMED